Looking for something with a little zip to add to your portfolio? Start the search with Marina Biotech, Inc. (PINK:MRNA), Zogenix, Inc. (NASDAQ:ZGNX), and Mimvi, Inc. (PINK:MIMV). Here's why.
Mimvi, Inc. shares have been trying to get over the hump at $0.42 for a while now. But, they haven't been able to clear it since the short-lived burst if brilliance back in late September. That is, until yesterday, when MIMV finally got - and stayed - above the ceiling at $0.42 with a close of $0.47. Perhaps just as telling is how all four key moving averages are all sloped upward, and all four are in a bullish order (20-day > 50-day > 100-day > 200-day). This looks like the real deal, and even more so on the weekly chart.
MIMV is a mobile-technology company. It's developed a search engine for mobile devices that specifically go out and find mobile apps, content, and products so users don't have to sift and hope in a sea of them. In simplest terms, Mimvi intuitively connects mobile app developers with advertisers so each is as relevant as possible to one another when users/browsers find one or the other. Yeah, it's complicated, but the company's site may make more sense out of it. Either way, the chart's budding.
Speaking of weekly charts, though the daily chart of Marina Biotech, Inc. looks just as compelling, it's the weekly chart that really puts the opportunity in perspective. For well over a year MRNA had been falling, but as of July the bleeding stopped and the bulls started to find a firmer footing. It wasn't until yesterday though - when the stock made its way back above the 200-day moving average line - that it became clear the bulls were serious, and that Marina was over the hump.
MRNA is the biotech company best known for its development of RNA-based therapies, and RNA interference. Its familial adenomatous polyposis program (CEQ508) is only in Phase 1, so there's still a lot of work to be done. But, the market rewards progress and promise, so there really is some speculative upside with Marina Biotech.
Last but not least (and again, largely based on a weekly chart), Zogenix, Inc. is knocking on the door of a bullish breakout, and just needs the right nudge. As you can see on the chart below, we've already seen a string of higher highs and higher lows from ZGNX since November of last year. But, when the middle resistance line (#2) gives way to the bullish effort and only the horizontal ceiling (red) at $3.00 and the upper resistance line (#3) are left, this chart could benefit from some serious slingshot action. It's just a matter of patience, though probably worth the wait.
ZGNX is the company that makes sumatriptan injection Sumavel DosePro... a needle-free way of delivering a treatment for migraines and other serious headaches. It's also working on Zohydro, which is essentially an extended-release hydrocodone that has already completed Phase 3 trials. Zogenix is still waiting on a final decision from the FDA, but the chart implies the odds favor an approval.... and the market has a funny way of being right about these things.